piflufolastat F 18

Phase 3Small molecule

Novartis

piflufolastat F 18 is one of 29 small molecule programs targeting Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Prostate CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

314 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

GM-CSF

YY-mAbs Therapeutics

Phase 3

8 2

Perflutren Lipid Microspheres

SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Phase 3

1 3

Androgen Deprivation Treatment

MMedical University of Vienna

Phase 3

1 4

piflufolastat F 18

Novartis

Phase 3

1 5

Antibiotic Prophylaxis

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 6

Trexall

Jazz Pharmaceuticals

Preclinical

—7

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 8

Duragesic

CCephalon

Preclinical

1 9

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 10

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Prostatic Neoplasm

NCT05849298

Clinical

Trials by Indication[1]

Metastatic1 trial

Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC

Withdrawn·LLantheus Medical Imaging·Phase 2/3·NCT07084909

Prostate Cancer1 trial

PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer

Active, not recruiting·LLantheus Medical Imaging·Phase 4·NCT06074510·274 enrolled

Prostatic Neoplasm1 trial

An International Prospective Open-label, Multi-center, Randomized, Non-comparative Phase II Study of Lutetium [177Lu] Vipivotide Tetraxetan (AAA617) Alone and Lutetium [177Lu] Vipivotide Tetraxetan (AAA617) in Combination With Androgen Receptor Pathway Inhibitors in Patients With PSMA PET Scan Positive Castration-Resistant Prostate Cancer

Active, not recruiting· Novartis logo

Novartis·Phase 2·NCT05849298·49 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for piflufolastat F 18. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — piflufolastat F 18 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for piflufolastat F 18. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novartis

piflufolastat F 18

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Metastatic1 trial

Prostate Cancer1 trial

Prostatic Neoplasm1 trial

References

Drug Info

Quick Facts

Related News